Evercore ISI Lowers Cencora (NYSE:COR) Price Target to $420.00

Cencora (NYSE:COR) had its target price dropped by analysts at Evercore ISI from $440.00 to $420.00 in a research note issued on Thursday, MarketBeat.com reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s price target points to a potential upside of 16.17% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Wells Fargo & Company lifted their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. UBS Group boosted their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $394.75.

Cencora Trading Up 9.6%

COR traded up $31.56 on Thursday, hitting $361.53. The company had a trading volume of 736,688 shares, compared to its average volume of 1,211,791. The company has a market cap of $70.13 billion, a PE ratio of 45.49, a PEG ratio of 1.72 and a beta of 0.68. Cencora has a 12-month low of $237.71 and a 12-month high of $377.54. The business’s fifty day simple moving average is $346.43 and its 200 day simple moving average is $325.27. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.73 EPS. Equities research analysts expect that Cencora will post 15.37 EPS for the current year.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,316 shares of company stock valued at $7,151,265 in the last 90 days. 0.38% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently added to or reduced their stakes in COR. Ameritas Advisory Services LLC purchased a new stake in shares of Cencora during the second quarter worth about $157,000. Valeo Financial Advisors LLC increased its stake in Cencora by 6.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,270 shares of the company’s stock worth $681,000 after buying an additional 130 shares in the last quarter. Sax Wealth Advisors LLC acquired a new position in shares of Cencora during the second quarter valued at approximately $222,000. Valmark Advisers Inc. lifted its position in shares of Cencora by 4.6% in the second quarter. Valmark Advisers Inc. now owns 1,109 shares of the company’s stock valued at $333,000 after acquiring an additional 49 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in shares of Cencora by 9.7% in the second quarter. Maryland State Retirement & Pension System now owns 8,899 shares of the company’s stock worth $2,668,000 after acquiring an additional 788 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat on EPS and showed improving margins, with adjusted metrics and profit per share topping estimates — a sign the specialty medicines strategy is supporting profitability. Reuters: Cencora beats quarterly profit estimates
• Positive Sentiment: Management raised fiscal‑2026 operating income growth targets (11.5%–13.5%) and lifted the sales outlook while integrating the OneOncology acquisition, which supports medium‑term revenue and margin expansion expectations. MSN: Cencora outlines operating income growth while integrating OneOncology TipRanks: Completes OneOncology acquisition
• Positive Sentiment: Cencora completed the OneOncology acquisition, which management says will drive specialty oncology volume — a strategic growth catalyst. BusinessWire: Q1 results / OneOncology
• Neutral Sentiment: The board declared a $0.60 quarterly dividend (ex‑dividend Feb 13), a modest yield that signals confidence but is unlikely to move the stock materially.
• Neutral Sentiment: Revenue was up 5.5% year‑over‑year to $85.9B, showing underlying growth despite the near‑term noise; full earnings call transcript and slide deck are available for details. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Revenue missed Street estimates by a small margin (~$86.12B expected vs. $85.9B reported); the top‑line miss triggered intra‑day selling and headlines emphasizing a revenue shortfall. MSN: Revenue miss MarketWatch: Falls on revenue miss
• Negative Sentiment: The stock underperformed peers in trading after results, suggesting investors favored cleaner top‑line beats across the sector and rotated away from even slight misses. MSN: Underperformance vs competitors
• Negative Sentiment: Market reaction reflects focus on near‑term revenue execution despite positive guidance — if upcoming quarters don’t show clear sales acceleration, sentiment could remain weak. Benzinga: Lifts sales outlook despite revenue miss

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.